Gland Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 06, 2023 at 05:44 am EST
Share
Gland Pharma Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 13,734.24 million compared to INR 10,444.04 million a year ago. Revenue was INR 14,265.79 million compared to INR 11,100.28 million a year ago. Net income was INR 1,940.82 million compared to INR 2,412.42 million a year ago. Basic earnings per share from continuing operations was INR 11.78 compared to INR 14.65 a year ago. Diluted earnings per share from continuing operations was INR 11.78 compared to INR 14.65 a year ago.
For the six months, sales was INR 25,821.17 million compared to INR 19,013.02 million a year ago. Revenue was INR 26,728.14 million compared to INR 20,413.17 million a year ago. Net income was INR 3,881.84 million compared to INR 4,704.11 million a year ago. Basic earnings per share from continuing operations was INR 23.57 compared to INR 28.58 a year ago. Diluted earnings per share from continuing operations was INR 23.56 compared to INR 28.57 a year ago.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
GLAND PHARMA LIMITED 
